Contemporary Pharmacologic Management of Heart Failure with Reduced Ejection Fraction: A Review

Author(s): Obiora Egbuche*, Bishoy Hanna, Ifeoma Onuorah, Emmanuela Uko, Yasir Taha, Jalal K. Ghali, Anekwe Onwuanyi

Journal Name: Current Cardiology Reviews

Volume 16 , Issue 1 , 2020

Become EABM
Become Reviewer

Abstract:

Heart failure with reduced ejection fraction (HFrEF) is defined as the presence of typical symptoms of heart failure (HF) and a left ventricular ejection fraction ≤ 40%. HFrEF patients constitute approximately 50% of all patients with clinical HF. Despite breakthrough discoveries and advances in the pharmacologic management of HF, HFrEF patients continue to pose a significant economic burden due to a progressive disease characterized by recurrent hospitalizations and need for advanced therapy. Although there are effective, guideline-directed medical therapies for patients with HFrEF, a significant proportion of these patients are either not on appropriate medications’ combination or on optimal tolerable medications’ doses. Since the morbidity and mortality benefits of some of the pharmacologic therapies are dose-dependent, optimal medical therapy is required to impact the burden of disease, quality of life, prognosis, and to curb health care expenditure. In this review, we summarize landmark trials that have impacted the management of HF and we review contemporary pharmacologic management of patients with HFrEF. We also provide insight on general considerations in the management of HFrEF in specific populations. We searched PubMed, Scopus, Medline and Cochrane library for relevant articles published until April 2019 using the following key words “heart failure”, “management”, “treatment”, “device therapy”, “reduced ejection fraction”, “guidelines”, “guideline directed medical therapy”, “trials” either by itself or in combination. We also utilized the cardiology trials portal to identify trials related to heart failure. We reviewed guidelines, full articles, review articles and clinical trials and focused on the pharmacologic management of HFrEF.

Keywords: Heart failure trials, heart failure, HFrEF, ejection fraction, GDMT, management, therapy.

[1]
Biglane JB, Becnel MF, Ventura HO, Krim SR. Pharmacologic therapy for heart failure with reduced ejection fraction: Closing the gap between clinical guidelines and practice. Prog Cardiovasc Dis 2017; 60(2): 187-97.
[http://dx.doi.org/10.1016/j.pcad.2017.08.006] [PMID: 28847619]
[2]
Agostoni P, Corrà U, Cattadori G, et al. Metabolic exercise test data combined with cardiac and kidney indexes, the MECKI score: A multiparametric approach to heart failure prognosis. Int J Cardiol 2013; 167(6): 2710-8.
[http://dx.doi.org/10.1016/j.ijcard.2012.06.113] [PMID: 22795401]
[3]
Zipse MM, Tzou WS. Sudden cardiac death in nonischemic cardiomyopathy: Refining risk assessment. J Cardiovasc Electrophysiol 2017; 28(11): 1361-6.
[http://dx.doi.org/10.1111/jce.13284] [PMID: 28670752]
[4]
Russo AM, Stainback RF, Bailey SR, et al. ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCMR 2013 appropriate use criteria for implantable cardioverter-defibrillators and cardiac resynchronization therapy: A report of the American College of Cardiology Foundation appropriate use criteria task force, Heart Rhythm Society, American Heart Association, American Society of Echocardiography, Heart failure society of america, society for cardiovascular angiography and interventions, Society of cardiovascular computed tomography, and society for cardiovascular magnetic resonance. Heart Rhythm 2013; 10(4): e11-58.
[http://dx.doi.org/10.1016/j.hrthm.2013.01.008] [PMID: 23473952]
[5]
Hsu JJ, Ziaeian B, Fonarow GC. Heart failure with mid-range (Borderline) Ejection Fraction: Clinical implications and future directions. JACC Heart Fail 2017; 5(11): 763-71.
[http://dx.doi.org/10.1016/j.jchf.2017.06.013] [PMID: 29032140]
[6]
Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA Guideline for the management of heart failure: A report of the american college of cardiology/american heart association task force on clinical practice guidelines and the heart failure society of America. J Card Fail 2017; 23(8): 628-51.
[http://dx.doi.org/10.1016/j.cardfail.2017.04.014] [PMID: 28461259]
[7]
Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: A report of the American college of cardiology foundation/american heart association task force on practice guidelines. J Am Coll Cardiol 2013; 62(16): e147-239.
[http://dx.doi.org/10.1016/j.jacc.2013.05.019] [PMID: 23747642]
[8]
Michel FS, Magubane M, Mokotedi L, Norton GR, Woodiwiss AJ. Sex-specific effects of adrenergic-induced left ventricular remodeling in spontaneously hypertensive rats. J Card Fail 2017; 23(2): 161-8.
[http://dx.doi.org/10.1016/j.cardfail.2016.09.017] [PMID: 27663100]
[9]
Gibbs M, Veliotes DG, Anamourlis C, et al. Chronic beta-adrenoreceptor activation increases cardiac cavity size through chamber remodeling and not via modifications in myocardial material properties. Am J Physiol Heart Circ Physiol 2004; 287(6): H2762-7.
[http://dx.doi.org/10.1152/ajpheart.00501.2004] [PMID: 15319203]
[10]
Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316(23): 1429-35.
[http://dx.doi.org/10.1056/NEJM198706043162301] [PMID: 2883575]
[11]
Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325(5): 293-302.
[http://dx.doi.org/10.1056/NEJM199108013250501] [PMID: 2057034]
[12]
Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med 1992; 327(10): 669-77.
[http://dx.doi.org/10.1056/NEJM199209033271001] [PMID: 1386652]
[13]
Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345(23): 1667-75.
[http://dx.doi.org/10.1056/NEJMoa010713] [PMID: 11759645]
[14]
Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362(9386): 772-6.
[http://dx.doi.org/10.1016/S0140-6736(03)14284-5] [PMID: 13678870]
[15]
McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362(9386): 767-71.
[http://dx.doi.org/10.1016/S0140-6736(03)14283-3] [PMID: 13678869]
[16]
A randomized trial of beta-blockade in heart failure. Circulation 1994; 90(4): 1765-73.
[http://dx.doi.org/10.1161/01.CIR.90.4.1765] [PMID: 7923660]
[17]
a randomised trial. Lancet 1999; 353(9146): 9-13.
[http://dx.doi.org/10.1016/S0140-6736(98)11181-9] [PMID: 10023943]
[18]
Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353(9169): 2001-7.
[http://dx.doi.org/10.1016/S0140-6736(99)04440-2] [PMID: 10376614]
[19]
Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344(22): 1651-8.
[http://dx.doi.org/10.1056/NEJM200105313442201] [PMID: 11386263]
[20]
Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): Randomised controlled trial. Lancet 2003; 362(9377): 7-13.
[http://dx.doi.org/10.1016/S0140-6736(03)13800-7] [PMID: 12853193]
[21]
Egbuche O, Ekechukwu I, Effoe V, et al. Effect of β-blocker therapy on hospital readmission and mortality in heart failure patients with concurrent cocaine use. J Cardiovasc Pharmacol Ther 2018; 23(6): 518-23.
[http://dx.doi.org/10.1177/1074248418778550] [PMID: 29793347]
[22]
Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341(10): 709-17.
[http://dx.doi.org/10.1056/NEJM199909023411001] [PMID: 10471456]
[23]
Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348(14): 1309-21.
[http://dx.doi.org/10.1056/NEJMoa030207] [PMID: 12668699]
[24]
Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364(1): 11-21.
[http://dx.doi.org/10.1056/NEJMoa1009492] [PMID: 21073363]
[25]
Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 1986; 314(24): 1547-52.
[http://dx.doi.org/10.1056/NEJM198606123142404] [PMID: 3520315]
[26]
Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004; 351(20): 2049-57.
[http://dx.doi.org/10.1056/NEJMoa042934] [PMID: 15533851]
[27]
Rame JE, Tam SW, McNamara D, et al. Dysfunctional corin i555(p568) allele is associated with impaired brain natriuretic peptide processing and adverse outcomes in blacks with systolic heart failure: results from the Genetic Risk Assessment in Heart Failure substudy. Circ Heart Fail 2009; 2(6): 541-8.
[http://dx.doi.org/10.1161/CIRCHEARTFAILURE.109.866822] [PMID: 19919978]
[28]
Packer M, Califf RM, Konstam MA, et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: The Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 2002; 106(8): 920-6.
[http://dx.doi.org/10.1161/01.CIR.0000029801.86489.50] [PMID: 12186794]
[29]
McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371(11): 993-1004.
[http://dx.doi.org/10.1056/NEJMoa1409077] [PMID: 25176015]
[30]
Velazquez EJ, Morrow DA, DeVore AD, et al. Rationale and design of the comParIson of sacubitril/valsartaN versus Enalapril on effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial. Am Heart J 2018; 198: 145-51.
[http://dx.doi.org/10.1016/j.ahj.2018.01.004] [PMID: 29653636]
[31]
Swedberg K, Komajda M, Böhm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): A randomised placebo-controlled study. Lancet 2010; 376(9744): 875-85.
[http://dx.doi.org/10.1016/S0140-6736(10)61198-1] [PMID: 20801500]
[32]
Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 2011; 364(9): 797-805.
[http://dx.doi.org/10.1056/NEJMoa1005419] [PMID: 21366472]
[33]
Allen LA, Turer AT, Dewald T, Stough WG, Cotter G, O’Connor CM. Continuous versus bolus dosing of Furosemide for patients hospitalized for heart failure. Am J Cardiol 2010; 105(12): 1794-7.
[http://dx.doi.org/10.1016/j.amjcard.2010.01.355] [PMID: 20538132]
[34]
The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336(8): 525-33.
[http://dx.doi.org/10.1056/NEJM199702203360801] [PMID: 9036306]
[35]
Adams KF Jr, Butler J, Patterson JH, et al. Dose response characterization of the association of serum digoxin concentration with mortality outcomes in the Digitalis Investigation Group trial. Eur J Heart Fail 2016; 18(8): 1072-81.
[http://dx.doi.org/10.1002/ejhf.584] [PMID: 27492641]
[36]
Acharya D, Sanam K, Revilla-Martinez M, et al. Infections, arrhythmias, and hospitalizations on home intravenous inotropic therapy. Am J Cardiol 2016; 117(6): 952-6.
[http://dx.doi.org/10.1016/j.amjcard.2015.12.030] [PMID: 26810859]
[37]
Hashim T, Sanam K, Revilla-Martinez M, et al. Clinical characteristics and outcomes of intravenous inotropic therapy in advanced heart failure. Circ Heart Fail 2015; 8(5): 880-6.
[http://dx.doi.org/10.1161/CIRCHEARTFAILURE.114.001778] [PMID: 26179184]
[38]
King JB, Shah RU, Sainski-Nguyen A, Biskupiak J, Munger MA, Bress AP. Effect of Inpatient Dobutamine versus Milrinone on Out-of-Hospital Mortality in Patients with Acute Decompensated Heart Failure. Pharmacotherapy 2017; 37(6): 662-72.
[http://dx.doi.org/10.1002/phar.1939] [PMID: 28475215]
[39]
Kusumoto FM, Schoenfeld MH, Barrett C, et al. 2018 ACC/AHA/HRS Guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay: Executive summary: A report of the american college of cardiology/american heart association task force on clinical practice guidelines, and the heart rhythm society. J Am Coll Cardiol 2019; 74(7): 932-87.
[http://dx.doi.org/10.1161/CIR.0000000000000627] [PMID: 30412710]
[40]
Gattis WA, O’Connor CM, Gallup DS, Hasselblad V, Gheorghiade M. Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: Results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial. J Am Coll Cardiol 2004; 43(9): 1534-41.
[http://dx.doi.org/10.1016/j.jacc.2003.12.040] [PMID: 15120808]
[41]
Tarantini L, Cioffi G, Opasich C, Di Lenarda A, Pulignano G, Del Sindaco D, et al. Pre-discharge initiation of beta-blocker therapy in elderly patients hospitalized for acute decompensation of chronic heart failure: An effective strategy for the implementation of betablockade in heart failure. Italian heart journal : official journal of the Italian Federation of Cardiology 2004; 5(6): 441-9.
[42]
Remme WJ, Riegger G, Hildebrandt P, et al. The benefits of early combination treatment of carvedilol and an ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction. The carvedilol and ACE-inhibitor remodelling mild heart failure evaluation trial (CARMEN). Cardiovasc Drugs Ther 2004; 18(1): 57-66.
[http://dx.doi.org/10.1023/B:CARD.0000025756.32499.6f] [PMID: 15115904]
[43]
Güvenç TS, Güvenç RC, Velibey Y, Tanık VO, Öz D, Eren M. Could ivabradine challenge be helpful for the diagnosis of intermittent sinoatrial node dysfunction in suspected patients? Med Hypotheses 2016; 92: 100-3.
[http://dx.doi.org/10.1016/j.mehy.2016.05.001] [PMID: 27241267]
[44]
Konstam MA, Gheorghiade M, Burnett JC Jr, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: The everest outcome trial. JAMA 2007; 297(12): 1319-31.
[http://dx.doi.org/10.1001/jama.297.12.1319] [PMID: 17384437]
[45]
Swedberg K, Young JB, Anand IS, et al. Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med 2013; 368(13): 1210-9.
[http://dx.doi.org/10.1056/NEJMoa1214865] [PMID: 23473338]
[46]
Kaneko Y, Floras JS, Usui K, et al. Cardiovascular effects of continuous positive airway pressure in patients with heart failure and obstructive sleep apnea. N Engl J Med 2003; 348(13): 1233-41.
[http://dx.doi.org/10.1056/NEJMoa022479] [PMID: 12660387]
[47]
Piepoli MF, Dimopoulos K, Concu A, Crisafulli A. Cardiovascular and ventilatory control during exercise in chronic heart failure: role of muscle reflexes. Int J Cardiol 2008; 130(1): 3-10.
[http://dx.doi.org/10.1016/j.ijcard.2008.02.030] [PMID: 18584895]
[48]
Piepoli MF, Crisafulli A. Pathophysiology of human heart failure: importance of skeletal muscle myopathy and reflexes. Exp Physiol 2014; 99(4): 609-15.
[http://dx.doi.org/10.1113/expphysiol.2013.074310] [PMID: 24293507]
[49]
Song T, Manoharan P, Millay DP, et al. Dilated cardiomyopathy-mediated heart failure induces a unique skeletal muscle myopathy with inflammation. Skelet Muscle 2019; 9(1): 4.
[http://dx.doi.org/10.1186/s13395-019-0189-y] [PMID: 30678732]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 1
Year: 2020
Page: [55 - 64]
Pages: 10
DOI: 10.2174/1573403X15666190709185011
Price: $65

Article Metrics

PDF: 39
HTML: 6